估计添加生物药物用于常规类风湿性关节炎治疗的患者特异性相对益处:个体参与者数据元分析
Yan Luo1,2, Konstantina Chalkou3,4, Satoshi Funada1,5
1Department of Health Promotion and Human Behavior, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
JAMA network open
|June 30, 2023
概括
在类风湿性关节炎治疗中添加克尔科利祖马布通常会改善治疗结果. 然而,对于基线概率很低或很高的患者来说,它的益处是不确定的,需要进一步评估个性化治疗策略.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
背景情况:
- 在传统的类风湿性关节炎治疗中添加生物药物的证据尚不清楚.
- 存在过度使用或延迟治疗的可能性.
研究的目的:
- 估计添加克尔科利祖马布 (certolizumab) 与常规类风湿性关节炎抗风湿药物的患者特异性益处.
- 分析基线特征如何影响治疗结果.
主要方法:
- 五项随机临床试验的个人参与者数据元分析.
- 使用了一种2阶段模型 (惩罚后勤回归和贝叶斯元回归).
- 估计了针对患者的低疾病活性或3个月后缓解的患者特异性结果.
主要成果:
- 在类风湿性关节炎患者中,添加 Certolizumab 改善了低疾病活性概率 (OR 6.31).
- 根据基线特征,福利差异很大.
- 估计风险差异为低或高基线概率的患者<10%.
结论:
- 塞尔科利祖马布通常在类风湿性关节炎治疗中更有效.
- 对于极端基线概率的患者来说,益处是不确定的,需要进一步评估.
- 互动应用程序有助于个性化治疗选择.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
200
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156


